We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CPIX

Price
4.35
Stock movement down
-1.01 (-18.84%)
Company name
Cumberland Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
65.08M
Ent value
99.89M
Price/Sales
1.77
Price/Book
2.66
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-0.30%
1 year return
191.95%
3 year return
30.22%
5 year return
5.43%
10 year return
-4.56%
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

DIVIDENDS

CPIX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.77
Price to Book2.66
EV to Sales2.72

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count14.96M
EPS (TTM)-0.77
FCF per share (TTM)-0.12

Income statement

Loading...
Income statement data
Revenue (TTM)36.79M
Gross profit (TTM)27.16M
Operating income (TTM)-7.12M
Net income (TTM)-10.87M
EPS (TTM)-0.77
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)73.83%
Operating margin (TTM)-19.36%
Profit margin (TTM)-29.54%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash17.46M
Net receivables11.31M
Total current assets35.24M
Goodwill914.00K
Intangible assets19.42M
Property, plant and equipment6.52M
Total assets76.75M
Accounts payable12.06M
Short/Current long term debt21.48M
Total current liabilities31.09M
Total liabilities52.28M
Shareholder's equity24.47M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-1.48M
Capital expenditures (TTM)232.52K
Free cash flow (TTM)-1.71M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-44.41%
Return on Assets-14.16%
Return on Invested Capital-26.54%
Cash Return on Invested Capital-4.17%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open5.48
Daily high5.48
Daily low4.35
Daily Volume208K
All-time high17.05
1y analyst estimate8.50
Beta-0.39
EPS (TTM)-0.77
Dividend per share-
Ex-div date-
Next earnings date11 Nov 2025

Downside potential

Loading...
Downside potential data
CPIXS&P500
Current price drop from All-time high-74.48%-3.04%
Highest price drop-93.78%-56.47%
Date of highest drop25 Nov 20249 Mar 2009
Avg drop from high-70.27%-11.04%
Avg time to new high1327 days12 days
Max time to new high3978 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
CPIX (Cumberland Pharmaceuticals Inc) company logo
Marketcap
65.08M
Marketcap category
Small-cap
Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Employees
91
Investor relations
-
SEC filings
CEO
A. J. Kazimi
Country
USA
City
Nashville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...